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Abstract 
Coronavirus disease 2019 (COVID-19) is rapidly spreading globally. As of July 3, 2020, the 
number of confirmed cases has been nearly 11 million with 521,000 fatalities. Severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) is accountable for COVID-19. Newly 
diagnosed and worsening cardiovascular disease are common complications in COVID-19 
patients, including acute cardiac injury, hypertension, arrhythmia, myocardial infarction, 
heart failure and sudden cardiac arrest. The mechanisms contributing to cardiac disease 
burden include hypoxemia, inflammatory factor storm, dysfunctional angiotensin converting 
enzyme 2 (ACE2), and drug-induced cardiac toxicity. Notably, the macrophages expressing 
ACE2 as direct host cells of SARS-CoV-2 secrete chemokine and inflammatory cytokines, as 
well as a decrease in cellular immune responses to SARS-CoV-2 infection due to elevated 
exhaustion levels and dysfunctional diversity of T cells, that may be accountable for the 
“hyperinflammation and cytokine storm syndrome” and subsequently acute cardiac injury 
and deteriorating cardiovascular disease in COVID-19 patients. However, no targeted 
medication or vaccines for COVID-19 are yet available. The management of cardiovascular 
disease in patients with COVID-19 include general supportive treatment, circulatory support, 
other symptomatic treatment, psychological assistance as well as online consultation. Further 
work should be concentrated on better understanding the pathogenesis of COVID-19 and 
accelerating the development of drugs and vaccines to reduce the cardiac disease burden and 
promote the management of COVID-19 patients, especially those with a severe disease 
course and cardiovascular complications. 
Key words: COVID-19, angiotensin converting enzyme 2, cardiovascular complications, 
inflammatory factor storm, endotheliitis, online consultation 
 
 
Introduction 
Coronavirus disease 2019 (COVID-19) is rapidly spreading globally. As of July 3, 2020, 
the number of confirmed cases has been nearly 11 million with 521,000 fatalities. Severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is accountable for COVID-19 and 
its sequence analysis has the smallest genetic distance from bat coronavirus and shares a 
79.5% sequence identity to SARS-CoV [1]. SARS-CoV-2 has a much more efficient 
transmission through active pharyngeal viral shedding at the time when symptoms are still 
mild and typical of upper respiratory tract infection, and spreads much faster than SARS-CoV 
[2]. SARS-CoV-2 can infect humans by gaining S protein-driven viral entry to a cell by 
utilizing angiotensin converting enzyme 2 (ACE2) [3, 4]. 
Patients with COVID-19 have multiple organ system dysfunction [5–7], and this was 
further confirmed by the latest pathological findings from systematic autopsy (37 cases) and 
percutaneous multiple organ biopsy (54 cases) [8]. According to the largest study to date [9] 
and recent data from other studies [5, 6, 8, 10–12], acute cardiac injury and underlying 
cardiovascular disease (CVD) are common in patients with COVID-19. On the other hand, 
patients with cardiovascular comorbidities are more prone to suffer from COVID-19, which 
in turn can cause deterioration of their CVD. This work reviewed the cardiovascular 
complications in COVID-19 patients, the underlying mechanisms, the management, and the 
prospect and challenges, aiming to reduce the cardiac disease burden and promote the 
management of COVID-19 patients, especially those with a severe disease course and 
cardiovascular complications (Fig. 1). 
 
COVID-19 and CVD 
Cardiac injury and myocarditis 
Abnormal elevation of cardiac injury biomarkers is widely present in patients with 
COVID-19 and is likely associated with infection-related myocarditis, right heart strain, 
and/or ischemia [10]. As for outcomes, the cardiac injury bio-markers are closely related to 
the disease progression and prognosis [10]. In a cohort study of patients with COVID-19, 
cardiac injury occurred in 19.7% of patients during hospitalization, and it was an independent 
risk factor for in-hospital mortality [10]. Cardiac injury was diagnosed mainly by an 
increased level of high-sensitivity cardiac troponin I (hs-cTnI). Patients with cardiac injury 
had a higher prevalence of chronic disease, including hypertension, diabetes, coronary artery 
disease, cerebrovascular disease, chronic heart failure (HF), and cancer. As for clinical 
outcome, cases with cardiac injury had much higher fatality rates (51.2%) than those without 
cardiac injury (4.5%). In a retrospective and multicenter cohort study of 191 patients with 
COVID-19 from hospitals in Wuhan, China, acute cardiac injury was observed in 17% of all 
cases, 59% of non-survivors and 1.0% of survivors. Hs-cTnI were 22.2 pg/mL and 3.0 pg/mL 
in non-survivors and survivors, respectively. In addition, levels of hs-cTnI were elevated in 
non-survivors compared with survivors throughout the clinical course, and increased with 
illness deterioration [6]. Taken together, these findings are supportive of the idea that 
myocardial injury is closely related to the severity and prognosis of patients with COVID-19.  
SARS-CoV-2 can cause myocarditis [13–15]. In a case report of a patient with the 
clinical presentation of myocarditis, the cardiac function sharply decreased and the heart size 
showed significant enlargement with troponin T of more than 10,000 ng/L, creatinine kinase-
MB 112.9 ng/L and B-type natriuretic peptide (BNP) was up to 21,025 ng/L [15]. Notably, 
there is no clear evidence that SARS-CoV-2 can directly impair the myocardium and cause 
viral myocarditis, because neither SARS-CoV-2 in myocardial tissue nor substantial damage 
were detected in heart tissue obtained from postmortem biopsies [13, 16]. The most recent 
pathological evidence from deceased patients undergoing necropsy indicated no viral 
particles in cardiac parenchymal cells, which is supportive of previous findings [17]. Thus, it 
appears that myocarditis is likely secondary to an inflammatory storm, right heart strain 
and/or ischemia. 
 
Arrhythmias in COVID-19 
Electrocardiogram abnormalities and arrhythmias were observed in more than 70% of 
patients with SARS and are also common in patients with COVID-19 [18–21]. More than 
74% of patients with COVID-19 showed electrocardiogram abnormalities and arrhythmias 
[22].  
Sinus tachycardia is commonly observed in COVID-19 patients reporting palpitations, 
whereas atrial tachycardia and atrial fibrillation are common in patients with symptoms of 
fatigue and chest tightness. Ventricular premature beats and paroxysmal ventricular 
tachycardia (VT) are common in patients with palpitations, dizziness, and even syncope. In 
severe cases, patients suffering from an inflammatory storm are at high risk of sustained VT 
and even ventricular fibrillation [22]. Patients with COVID-19 who develop cardiac injury 
often present with sinus tachycardia [19]. Bradyarrhythmias are infrequent in patients with 
COVID-19, but they seem to occur suddenly and most of these cases are due to high-level 
atrioventricular block [22]. The QTc interval was 431 ms in patients with COVID-19 and 
12.9% of cases showed prolonged QTc interval [22]. Hydroxychloroquine and azithromycin, 
which are used as off-label drugs to treat COVID-19 in some areas, can further enhance QT 
prolongation and may predispose patients with and without underlying CVDs to potentially 
life-threatening torsade de pointes VT [23–25]. 
The abnormal electrocardiogram (ECG) findings were related to the underlying severity 
of COVID-19 patients. In a case series of COVID-19 patients with ST-segment elevation, 
72% of cases died in the hospital [20]. Compared with the non-invasive care unit (ICU) 
group, the proportion of abnormal Q waves was higher in the ICU group (33.3% vs. 3.9%) 
[22]. Abnormal Q waves often indicate myocardial necrosis. Viral infection can aggravate the 
original myocardial disease and increase the risk of critical illness through mechanisms such 
as immune damage, aggravation of microvascular ischemia and induction of apoptosis.  
 
Heart failure and sudden cardiac arrest  
Heart failure is common in cases with COVID-19 [5, 26]. In a retrospective study of 112 
cases with COVID-19 divided into non-survivors (17, 15.18%) and survivors (95, 84.82%), 
there were 27 (28.42%) and 13 (76.47%) cases with HF, respectively. The most recent report 
to date from Italy indicated that the second most common comorbidity in patients with 
COVID-19 admitted to ICUs were cardiomyopathy and HF. This finding is also supportive of 
the idea that HF may predispose individuals with COVID-19 to a worsening clinical outcome 
[5]. Even among COVID-19 patients without chronic underlying disease, those patients 
developing acute HF within a short time are prone to sudden cardiac arrest and the course of 
the disease often deteriorates rapidly [18].  
Heart failure in cases with COVID-19 appears secondary to acute respiratory distress 
syndrome (ARDS), acute respiratory failure, or other serious respiratory complications [18]. 
Pulmonary artery hypertension and pulmonary heart disease due to increased pulmonary 
vascular resistance leads to increased right ventricular strain and right HF. One should be 
alert to HF to reduce mortality. Moreover, COVID-19 patients at risk often have diastolic 
dysfunction and/or microvascular disease with increased left-sided filling pressures, which in 
case of a superinfection and fluid overload, can aggravate left-HF and increase pulmonary 
edema thereby deteriorating ARDS.  
 
Acute coronary syndrome  
Acute coronary syndrome (ACS) ranks second after respiratory failure as the cause of fatality 
[22, 26], and most cases in patients with COVID-19 are secondary to severe respiratory 
failure. Lactic acid accumulation and hypoxia caused by respiratory failure and 
hypercoagulation accelerates the occurrence of acute myocardial infarction (AMI), especially 
in cases with underlying CVD. Emergency percutaneous coronary intervention (PCI) should 
be considered to improve the ischemia-reperfusion injury. Given the lack of negative pressure 
cardiac catheterization chambers during the COVID-19 pandemic, particularly in regions 
with less advanced health-care systems, PCI as an emergency procedure has to be 
reconsidered, particularly for non-ST-segment elevation myocardial infarction, and 
prehospital emergency intravenous thrombolytic therapy is generally recommended. Expert 
consensus and guidelines on the management of ACS emphasizing the emerging role of 
intravenous thrombolytic therapy during the COVID-19 pandemic have been presented by 
scientific societies or groups on the front line against COVID-19 [27–29].  
 
Hypertension 
Half of cases with COVID-19 have comorbidities and the most common one is systemic 
arterial hypertension, which is associated with the severity of COVID-19 and in-hospital 
death [6, 7]. In a retrospective cohort study, 30% of cases had hypertension and the 
prevalence of hypertension in non-survivors (48%) was twice as much as that in non-
survivors (23%) [6]. In a recent study, hypertension was the most common comorbidity 
(49%) in patients with laboratory-confirmed COVID-19 referred for ICU admission in the 
Lombardy region of Italy [5]. In a study by Huang, 15% of cases have hypertension and the 
ICU group had higher systolic blood pressure as compared to the non-ICU group [7]. 
 
Mechanisms of CVD in COVID-19 
At present, the mechanisms underlying cardiac injury and other CVDs in patients with 
COVID-19 are not well defined. Possible mechanisms are the following: an excessive 
inflammatory reaction, severe hypoxemia, dysfunctional ACE2 with upregulation of the 
RAS, cardiac toxicity due to drug-drug interactions such as azithromycin and 
hydrochloroquine causing acquired long QT syndrome with torsade de pointes ventricular 
tachycardia. 
 
Hypoxemia  
Respiratory infection leading to insufficient oxygen supply is the main cause of hypoxemia 
[5, 6, 17]. In the most recent work by Wang et al. [17], pathologic investigations of fatal cases 
undergoing necropsy provide new evidence contributing to the severe dysfunction of 
ventilation and gas exchange obstruction in patients with COVID-19. The gross anatomy of 
the lungs showed moderate bilateral pleural effusion and pleural adhesion in 2 patients and 
hepatization of lung tissue was observed. As for microscopic manifestation, a massive serous 
and fibrinoid exudate was observed in the alveolar spaces [17]. On the other hand, infection-
induced increased metabolic requirements need an enhanced oxygen supply, which in turn 
results in severe hypoxemia. And hypoxemia, in turn, may lead to increased anaerobic 
fermentation and subsequently acidosis, oxygen free radicals, and ultimately cardiac injury. 
Among COVID-19 patients with underlying CVD the risk of hypoxemia is increased. And 
this hypoxemia can aggravate cardiac injury and accelerate the progression of CVD. These 
findings may explain the high rate of ACS, acute HF and fatal arrhythmias in severe cases. 
Notably, emerging pathological evidence from post mortem examination indicates pulmonary 
hemorrhage which may also be accountable for hypoxemia induced by suboptimal ventilation 
[17]. However, the causes of hypoxemia and its impact on the progression of ARDS needs to 
be further elucidated. 
 
Inflammatory factor storm  
Cytokine storm plays a vital role in the pathogenesis of coronavirus-caused tissue 
damage and entails a vast amount of cardiac injury in patients infected by coronaviruses [6, 7, 
17, 30]. As for patients with COVID-19, the level of interleukin-6 (IL-6) was higher in non-
survivors than in survivors throughout the clinical course, and increased with illness 
deterioration [6]. In Huang’s study, higher levels of plasma cytokines and chemokines were 
higher in ICU patients than non-ICU patients [7].  
The most recent evidence provides novel contributions for a better understanding of the 
immune responses during COVID-19 [17, 30, 31]. First, pathological evidence obtained from 
fatal cases due to COVID-19 indicates that a direct viral infection of the macrophages 
expressing ACE2 results in the extraordinary aggregation and activation of macrophages. 
These macrophages infected by SARS-CoV-2 secrete chemokines and inflammatory 
cytokines including IL-6, IL-10 and tumor necrosis factor alpha (TNFα). These findings are 
supportive of the idea that macrophages act as direct host cells of SARS-CoV-2 and potential 
drivers of “inflammatory factor storm” or “cytokine storm” in COVID-19 [17]. On the other 
hand, decreased cellular immune responses to SARS-CoV-2 infection were also identified. 
Elevated exhaustion levels and dysfunctional diversity of T cells may be another mechanism 
accountable for the “cytokine storm syndrome” in COVID-19 [30]. Previous studies indicated 
that multi-functional T cells can better control human immunodeficiency virus and are 
correlated with better outcomes during vaccination. However, in Zhang and colleagues’ study, 
SARS-CoV-2 infection caused dysfunctional CD4+ T cells and promoted extraordinary 
activation and possibly subsequent exhaustion of CD8+ T cells. Moreover, severe cases 
infected by SARS-CoV-2 showed significantly decreased frequency of multi-functional 
CD4+ T cells compared with healthy controls and mild cases. These findings are supportive 
of the idea that compared to other coronaviruses, SARS-CoV-2 may possess a unique 
immunopathological mechanism which predisposes infected cases to deteriorate rapidly.  
 
Dysfunctional ACE2 
Previous data indicated that coronavirus can lead to ACE2 dysfunction and subsequently 
abnormal activation of RAS, eventually resulting in an hyperinflammatory reaction. The 
down-regulation of ACE2 was observed in animal models of SARS and H7N9 infection, and 
this can be counter regulated by angiotensin receptor blockers (ARBs) [32, 33]. As for the 
cardiovascular system, decreased ACE2 expression in the myocardium was observed in 
animals and patients infected by SARS-CoV [34]. Infection with the human SARS-CoV in 
mice led to an ACE2-dependent myocardial infection with a marked decrease in ACE2 
expression, which was supportive of a critical role of ACE2 in mediating SARS-CoV 
infection in the heart. In patients infected by SARS-CoV, the virus was also detected in 
autopsied human hearts and its presence was associated with marked reductions in ACE2 
protein expression [34]. Though no evidence of SARS-CoV-2 directly infecting myocardium, 
based on the information that SARS-CoV-2 and SARS-CoV share the similar structure and 
function [4, 35]. We can make some rational and scientific inferences that SARS-CoV-2 may 
lead to cardiac injury by affecting ACE2 function. Notably, emerging evidence from post-
mortem analysis are supportive of this idea [36]. In a serial section of tissues, Zsuzsanna et al. 
[36] found evidence of direct SARS-CoV-2 infection of the endothelial cell and diffuse 
endothelial inflammation. The fact that endothelial cells of multiple systems expressing 
dysfunctional ACE2 receptor due to direct SARS-CoV-2 infection of the endothelium or 
immune-mediated facilitates the induction of endotheliitis and may be the main mechanism 
underlying multiple system organ failure, including CVD [36]. Drugs or vaccines targeting 
these processes may provide a therapeutic target.  
 
Adverse effect of drugs  
Given the fast spread and high transmission rates of COVID-19, there are many 
programs aiming at developing pharmaceutical drugs for treatment and prevention of 
COVID-19. While ongoing and future studies should be actively supported, caution is needed 
for the off-label use of previously approved drugs due to cardiac toxicity, especially in severe 
cases with multiple comorbidities and polypharmacy [5–7, 21]. In a small study conducted by 
Philippe et al. [37] attracting much attention, hydroxychloroquine treatment was significantly 
associated with viral load reduction/disappearance in the pharynx of COVID-19 patients. In 
China, hydroxychloroquine is already recommended in the Chinese Clinical Guidance for 
COVID-19 Pneumonia Diagnosis and Treatment. Other countries have followed these 
recommendations. However, clinical and in vitro experimental evidence has reported 
hydroxychloroquine-induced cardiac toxicity [21, 38]. When hydroxychloroquine was 
prescribed in severe cases, patients with underlying CVD are prone to hydroxychloroquine-
induced cardiac toxicity and this is likely to aggravate underlying disease. In a recent study, 
patients with COVID-19 treated with hydroxychloroquine and azithromycin had severe QTc 
prolongation but they had a normal QTc at baseline [21]. Another factor should also be 
considered, namely synergistic toxicity. Patients with COVID-19 are often concurrently 
prescribed a drug in combination with many other drugs. 
 
Management of CVD during the COVID-19 pandemic 
In the management of COVID-19, the treatment of patients with acute myocardial injury 
and underlying CVD adheres to the principles of comprehensive treatment. In addition to the 
general and supportive treatment, antiviral therapy is recommended in expert consensus and 
guidelines. However, there are no targeted antiviral agents for SARS-CoV-2. Though 
lopinavir/ritonavir and hydroxychloroquine showed effectiveness in some cases, recent 
evidences from a randomized, controlled, open-label trial published in ‘New England Journal 
of Medicine’ [39] showed that no benefit was observed with lopinavir/ritonavir treatment 
beyond standard care in hospitalized adult patients with severe COVID-19. As for 
chloroquine, the article by Philippe et al. [40] to support the potential of the chloroquine has 
been retracted due to “expected standard”. In addition, the same dosing regimen reported by 
Philippe et al. [41] showed no evidence of a strong antiviral activity or clinical benefit of the 
combination of hydroxychloroquine and azithromycin for the treatment of the hospitalized 
patients with severe COVID-19. Thus, the therapeutic value and safety of these antiviral 
agents are still under investigation with ongoing trials. 
 
Respiratory support  
Depending on the clinical condition, supplemental oxygen and invasive respiratory 
support should be considered as expert consensus guidelines recommend. However, more 
awareness is needed when ICU capacity is overwhelmed. Viral transmission through exhaled 
air dispersion during respiratory support can accelerate interpersonal transmission in the 
airtight wards, and this situation may be worse when two or more patients are using a shared 
ventilator due to limited heath care resources [42].  
 
Anti-inflammatory treatment 
As for inflammatory storm, the administration of immunoglobulins can effectively 
ameliorate the strong immune response to SARS-CoV-2. Recent pathological evidence from 
post mortem examinations indicated characteristic abnormalities of the mucous plug with 
fibrinous exudate in the alveoli and the activation of alveolar macrophages [17]. These 
findings are supportive of the potential of the IL-6 receptor antagonist tocilizumab for severe 
and critically ill patients with COVID-19. The use of glucocorticoids is controversial and 
currently not recommended in the current interim guidance from the World Health 
Organization on clinical management of COVID-19 due to its potential inhibition of viral 
clearance and prolongation of the duration of viremia [43]. Both artificial liver support 
systems and continuous renal replacement therapy showed potential in the treatment of SARS 
and MERS, and are also recommended in the guidelines of the Chinese National Health 
Commission against COVID-19. 
 
Drug treatment 
As for those with CVD, statins, β-blockers, ACEIs/ARBs, and antiplatelet and 
anticoagulant agents should be actively prescribed as appropriate to protect the 
cardiovascular system. As for acute myocardial infarction, emergency PCI should be the first 
choice if a negative pressure catherization room is available. The strategies to treat 
arrhythmias in patients with COVID-19 should be according to the type of arrhythmia and the 
hemodynamic status of the patient.  
Most notably, the use of ACEIs/ARBs in patients without CVD are not recommended. 
Whether ACEIs/ARBs are beneficial in COVID-19 patients without hypertension, HF, 
ischemic cardiomyopathy or other diseases are still under investigation. 
 
Device treatment  
Regarding cardiac pump failure, life supportive treatments such as a temporary 
pacemaker, left ventricular assist device, and extracorporeal membrane oxygenation (ECMO) 
should also be considered early in the disease course. Given that severe or critical COVID-19 
cases who can be successfully weaned off ECMO have been reported to be rare, some have 
argued that ECMO might not be an optimal treatment strategy during the COVID-19 
pandemic. Herein provided is one case supportive of ECMO as a life-saving procedure to 
provide both respiratory and cardiac support for patients suffering from cardiac and 
respiratory failure. This case is a patient with laboratory-confirmed COVID-19. Her 
condition rapidly deteriorated under conventional therapy. VV-ECMO was used to provide 
both respiratory and cardiac support. She had fully recovered from the condition that 
necessitated the use of ECMO after about 7 weeks. The ECMO treatment in this case is 
supportive of the use of ECMO during the COVID-19 pandemic. 
 
Psychological assistance 
The relationship of mental disorders and CVD is well known. Mental health disorders, 
such as anxiety, fear, depression, and insomnia are very common in patients, health 
professionals, and the general public [44, 45]. Governments, organizations, and institutions 
have implemented policies to improve these mental health challenges. Though the potential 
of mental health disorders to aggravate underlying CVD or induce acute cardiac injury during 
the COVID-19 pandemic remains unknown, psychological assistance should be provided as 
soon as possible by a hotline or online consultation [44–46].  
 
Online consultation  
Given that COVID-19 has overwhelmed many healthcare systems, non-infectious 
disease, intensivists, and cardiologist physicians have been recruited from other medical 
specialties, without adequate training, to play this role. During the COVID-19 pandemic in 
China, specialists in other cities were invited for online consultation for the management of 
severe and critical cases in hospitals. When COVID-19 was rapidly spreading all over the 
world in March of 2020, hospitals in China also shared clinical experiences with specialists in 
Italy and the United States. Fast and effective online consultation are important when the 
appropriate specialists are not available. Social distancing however does not mean social 
isolation. We should all stand together against the COVID-19 pandemic globally with the 
help of an online consultation system. 
Last but importantly, thinking ahead is a precondition for protecting hearts and reducing 
mortality. We must bear in mind the clinical presentation and other clues of myocardial injury 
in this challenging disease, and carefully monitor cardiac function and myocardial injury. 
Based on our experience in Wuhan hospitals, the typical clinical manifestation with angina 
pectoris, shortness of breath and dyspnea is often paralleled with increased cardiac injury 
biomarkers. However, an atypical clinical presentation of cardiac injury is often blunted by 
the symptoms of lung infection. It should be carefully identified to take action before the 
condition rapidly deteriorates. 
 
Prospect and challenges 
Cardiovascular diseases in patients with COVID-19 are accountable for the poor 
prognosis especially in > 50-year old adults with underlying CVD. Recently emerging 
evidence helps explain the structural features of the SARS-CoV-2, the way it interacts with 
human cells and its infection ability [4, 47–49], however, why SARS-CoV-2 has a much 
more efficient transmission and spreads much faster than SARS-CoV though they belong to 
the same species is not known. As for CVDs, the exact mechanism by which SARS-CoV-2 
results in dysfunction of the cardiovascular system, the relationship of SARS-CoV-2, ACE2 
and ACEI/ARB remains unknown. Second, it is essential to develop targeted antiviral drugs 
and vaccines with strict standards using standard clinical-trial parameters. Third, there are 
some concerns that when SARS-CoV-2 is widely circulating, SARS-CoV-2 may result in an 
outbreak to overwhelm the healthcare systems. Fourth, there are many silent coronavirus 
spreaders who are infected by SARS-CoV-2 but show no symptoms. Less is known about 
their infectiousness and prognosis. Fifth, as COVID-19 is rapidly spreading across the world, 
enormous and scarce medical resources are allocated to combat the unprecedented pandemic. 
These efforts aiming to contain the circulation of SARS-CoV-2 will inevitably lead to 
absolute scarcity in other fields. Numerous pleas have been received from patients with 
underlying CVD, diabetes mellitus, and other conditions for routine clinical services such as 
elective PCI, ablation of cardiac arrhythmias, or cardiac rehabilitation. When most if not all 
of those patients take a back seat during the unpredictable COVID-19 pandemic, they will be 
critically affected and considered as a high-risk population of severe and critical conditions 
prone to SARS-CoV-2 infection. Therefore, preparedness for maximizing scarce medical 
resources across all patients is essential. 
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Figure 1. Coronavirus disease 2019 (COVID-19) and cardiovascular disease; SARS-CoV-2 
— severe acute respiratory syndrome coronavirus 2; ACE2 — angiotensin-converting 
enzyme 2; Ang — angiotensin; AT1R — angiotensin II type 1 receptor; TNF-α — tumor 
necrosis factor alpha; IL-10 — interleukin-10; IL-6 — interleukin-6. 
 

